IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes

IceCure Medical Completes First Patient Treatment in ChoICE Post-Marketing Study

IceCure Medical has successfully treated the first patient in its ChoICE post-marketing study, which evaluates the ProSense cryoablation system for treating low-risk breast cancer.

IceCure Medical Enrolls First Patients in FDA-Approved ChoICE Study

IceCure Medical has officially begun patient enrollment for its post-market clinical study of the ProSense cryoablation system for breast cancer at two U.S. sites.

IceCure Medical Announces First Two Patients Enrolled In 400-Patient U.S. Post-Marketing Study Of ProSense Breast Cancer Cryoablation

IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting

Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation